Pregnancy, cytokines, and disease activity in systemic lupus erythematosus
- PMID: 15593367
- DOI: 10.1002/art.20837
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus
Abstract
Objective: To evaluate levels of selected cytokines and soluble receptors involved in the humoral immune response during pregnancy in systemic lupus erythematosus (SLE) patients.
Methods: Seventeen consecutive SLE patients and 8 matched healthy controls were prospectively studied during pregnancy. Sera were obtained within the last 3 months prior to pregnancy; at 9, 17, and 29 weeks of pregnancy; and at 1 month after delivery. Serum levels of interleukin-10 (IL-10), interleukin-6 (IL-6), and soluble tumor necrosis factor receptors p55 (sTNFR I) and p75 (sTNFR II) were evaluated. SLE activity was measured by the European Consensus Lupus Activity Measurement score modified for pregnancy.
Results: IL-10 serum levels were found to be higher (P <0.0001) in patients than in controls before conception, and still higher (P <0.0001) in SLE patients during gestation, without intertrimester changes. In SLE patients, IL-6 serum levels did not increase in the third trimester of pregnancy, as was observed in controls (P=0.011). No significant differences between SLE patients and controls were found in either sTNFR I or II levels or profiles before and during pregnancy. IL-10 and sTNFR I levels were significantly higher during pregnancy and postpartum in SLE patients with active disease (P=0.03 and P=0.01, respectively).
Conclusion: The levels of some cytokines involved in the humoral immune response seem to be modified in the peripheral circulation of pregnant SLE patients. The most relevant modifications are the lower than expected increase of IL-6 in the third trimester of gestation and persistently high levels of IL-10 during pregnancy.
Similar articles
-
Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.J Rheumatol. 2003 Oct;30(10):2133-9. J Rheumatol. 2003. PMID: 14528506
-
Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.Clin Biochem. 2005 Feb;38(2):134-41. doi: 10.1016/j.clinbiochem.2004.11.002. Clin Biochem. 2005. PMID: 15642275
-
Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.Anticancer Res. 2001 Jul-Aug;21(4B):3053-9. Anticancer Res. 2001. PMID: 11712810
-
Estrogens in pregnancy and systemic lupus erythematosus.Ann N Y Acad Sci. 2006 Jun;1069:247-56. doi: 10.1196/annals.1351.022. Ann N Y Acad Sci. 2006. PMID: 16855151 Review.
-
[Cytokines in systemic lupus erythematosus].Przegl Lek. 1996;53(8):623-6. Przegl Lek. 1996. PMID: 8999465 Review. Polish.
Cited by
-
Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.J Clin Immunol. 2007 Sep;27(5):461-6. doi: 10.1007/s10875-007-9104-0. Epub 2007 Jun 21. J Clin Immunol. 2007. PMID: 17587156
-
Association of Insulin Resistance with Serum Interleukin-6 and TNF-α Levels During Normal Pregnancy.Biomark Insights. 2011 Jan 12;6:1-6. doi: 10.4137/BMI.S6150. Biomark Insights. 2011. PMID: 21461291 Free PMC article.
-
Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.Nat Rev Rheumatol. 2014 Dec;10(12):740-51. doi: 10.1038/nrrheum.2014.144. Epub 2014 Aug 26. Nat Rev Rheumatol. 2014. PMID: 25155581 Review.
-
Benefit of pregnancy in inflammatory arthritis.Ann Rheum Dis. 2005 Jun;64(6):801-3. doi: 10.1136/ard.2005.037580. Ann Rheum Dis. 2005. PMID: 15897301 Free PMC article. Review. No abstract available.
-
The Hopkins Lupus Pregnancy Center: ten key issues in management.Rheum Dis Clin North Am. 2007 May;33(2):227-35, v. doi: 10.1016/j.rdc.2007.01.003. Rheum Dis Clin North Am. 2007. PMID: 17499704 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials